Recursion Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Recursion Pharmaceuticals şirketinin toplam hissedar öz sermayesi $524.6M ve toplam borcu $1.1M olup, bu da borç-öz sermaye oranını 0.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $726.5M ve $201.9M dir.

Anahtar bilgiler

0.2%

Borç/özkaynak oranı

US$1.09m

Borç

Faiz karşılama oranı	n/a
Nakit	US$427.65m
Eşitlik	US$524.56m
Toplam yükümlülükler	US$201.94m
Toplam varlıklar	US$726.50m

Son finansal sağlık güncellemeleri

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Jan 31

Recent updates

Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline

Nov 20

Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week

Nov 10

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk

Nov 08

Recursion: AI Is Only As Good As The Data

Sep 11

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 04

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

May 22

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Apr 10

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Mar 20

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Jan 31

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Jan 12

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

Dec 09

What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

May 09

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RXRX 'nin kısa vadeli varlıkları ( $474.2M ) kısa vadeli yükümlülüklerini ( $108.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: RXRX şirketinin kısa vadeli varlıkları ( $474.2M ) uzun vadeli yükümlülüklerini ( $93.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RXRX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: RXRX şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: RXRX şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: RXRX serbest nakit akışı her yıl % 37.9 1.3 yıl yetecek nakit akışına sahip olacaktır.

Recursion Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Recent updates

Recursion Appoints Ben Taylor as Chief Financial Officer

Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline

Co-Founder exercised options and sold US$302k worth of stock

Recursion Pharmaceuticals, Inc. Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Recursion Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Co-Founder exercised options and sold US$245k worth of stock

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Recursion: AI Is Only As Good As The Data

Co-Founder exercised options and sold US$244k worth of stock

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion Pharmaceuticals, Inc. Announces to Appoint David Hallett, Ph.D as Chief Scientific Officer

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Co-Founder notifies of intention to sell stock

Price target decreased by 11% to US$11.57

Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) dropped from Russell 3000E Value Index

Recursion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999995 million.

Recursion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999995 million.

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must

Co-Founder notifies of intention to sell stock

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

Recursion Announces Completion of NVIDIA-Powered BioHive-2

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Chief Financial Officer exercised options and sold US$260k worth of stock

Recursion Appoints Najat Khan as Chief R&D Officer and Chief Commercial Officer

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Co-Founder notifies of intention to sell stock

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Co-Founder & Director notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. Appoints Kristen Rushton as Chief Business Operations Officer

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recursion Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024

Recursion Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Recursion Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. Announces Transition of Shafique Virani from the Chief Business Officer into Senior Strategic Advisor

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Recursion Unveils Lowe Drug Discovery Software At the J.P. Morgan Healthcare Conference

Co-Founder notifies of intention to sell stock

Price target decreased by 23% to US$12.33

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

Co-Founder notifies of intention to sell stock

Chief Financial Officer exercised options and sold US$266k worth of stock

Consensus EPS estimates fall by 18%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. Announces Completion of Phase 1 Study for Rec-3964 for Clostridioides Difficile Infection

Chief Financial Officer notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Independent Director notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. announced that it has received $50.000001 million in funding from NVIDIA Corporation

New major risk - Share price stability

Recursion Announces Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation Has Fully Enrolled

Co-Founder & Director notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Cyclica Inc.

Recursion Pharmaceuticals, Inc. Appoints David Mauro as Chief Medical Officer

Price target decreased by 10.0% to US$14.86

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a Share Purchase Agreement to acquire Valence Discovery for $47.5 million.

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a Share Purchase Agreement to acquire Cyclica Inc. for $40 million.

What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today